Novel Experimental COVID-19 Therapies Affecting Host Response (NECTAR) is a Phase II, multi-arm, blinded, randomized placebo-controlled trial targeting macro-, micro-immunothrombosis, vascular hyperinflammation and hypercoagulability in hospitalized patients with COVID-19 (ACTIV-4 Host Tissue). The objective is to determine the impact of modulating the host tissue response on mortality and outcomes related to ARDS. The research objectives are to evaluate each agent with respect to speed of recovery, mortality, illness severity, and hospital resource utilization. We hypothesize the administration fostamatinib will improve clinical outcomes and will result in improvement in oxygen-free days through day 28.

Please see ClincalTrials.gov#NCT04924660 for more information.